Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-25-004961
Filing Date
2025-06-18
Accepted
2025-06-18 19:37:28
Documents
1
Period of Report
2025-06-16

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 4164
  Complete submission text file 0001562180-25-004961.txt   5579
Mailing Address C/O ONYX PHARMACEUTICALS, INC. 2100 POWELL STREET EMERYVILLE CA 94608
Business Address
Brege Laura (Reporting) CIK: 0001365619 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40236 | Film No.: 251058283

Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Issuer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)